This work has been partially supported by research grant from Terumo BCT as well as by grants FIS (CP04-00112, PS09/00664) (Fondo de Investigaciones de la Seguridad Social), German Jose Carreras Leukemia Foundation (R 07/41v), SAF2009-10365, SAF2011-28214 (Ministerio de Ciencia y Tecnología), and RD06/ 0009/1003 (Red HERACLES, Instituto de Salud Carlos III).
Automated preparation of whole blood–derived platelets suspended in two different platelet additive solutions and stored for 7 days
Version of Record online: 30 MAY 2013
© 2013 American Association of Blood Banks
Volume 54, Issue 2, pages 426–433, February 2014
How to Cite
Cid, J., Magnano, L., Molina, P., Diaz-Ricart, M., Martínez, N., Maymó, R. M., Puig, L., Lozano, M., Escolar, G. and Galán, A. M. (2014), Automated preparation of whole blood–derived platelets suspended in two different platelet additive solutions and stored for 7 days. Transfusion, 54: 426–433. doi: 10.1111/trf.12283
- Issue online: 11 FEB 2014
- Version of Record online: 30 MAY 2013
- Manuscript Revised: 30 APR 2013
- Manuscript Accepted: 30 APR 2013
- Manuscript Received: 27 FEB 2013
The Atreus system (Terumo BCT) automates the preparation of blood components from whole blood donations. Intermediate platelet (PLT) products can be pooled manually or with the OrbiSac (Terumo BCT) and suspended in different PLT additive solutions (PASs) to obtain PLT concentrates (PCs). The aim of our study was to compare the in vitro PLT quality of PCs obtained with either the Atreus 2C+ and the OrbiSac or the Atreus 3C and suspended in PAS-II or PAS-IIIM during storage for up to 7 days.
Study Design and Methods
We prepared eight PCs from buffy coats obtained with Atreus 2C+, pooled with the OrbiSac, and suspended in PAS-II and eight PCs from interim PLT units obtained with the Atreus 3C and suspended either in PAS-II or in PAS-IIIM. We measured volume, PLT content, and mean PLT component and performed metabolic assays (pH, glucose, lactate, pO2, and pCO2) and flow cytometry analyses (GPIb, GPIIbIIIa, GPIV, CD62P, CD63, von Willebrand factor [vWF], fibrinogen, Factor V, and annexin V).
PCs prepared with the Atreus 3C showed lower volume and higher PLT concentration when compared with PCs prepared with the Atreus 2C+ and the OrbiSac (p < 0.05). Glucose consumption rate and the expression of CD62P, CD63, and vWF were lower in PCs suspended in PAS-IIIM when compared with PCs suspended in PAS-II (p < 0.05).
PCs prepared with the Atreus 3C and suspended in PAS-IIIM preserve satisfactorily the in vitro PLT quality during 7-day storage. PLT activation during a 7-day storage period was lower when the storage solution was PAS-IIIM in comparison with PAS-II.